Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPL-387 in Well-Controlled Recurrent Pericarditis
NCT07288216Phase 2Recruiting
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of KPL-387 in recurrent pericarditis, sponsored by Kiniksa Pharmaceuticals. Started Mar 2026; status: recruiting.
02
Drugs
KPL-387
03
Conditions
recurrent pericarditis
Beyond the preview
Go deeper on NCT07288216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288216.